Matthew Kalnik
Gründer bei Hedgerow Consulting LLC
Profil
Matthew Walter Kalnik is the founder of Hedgerow Consulting LLC, Antidote Therapeutics, Inc. He previously held positions as Executive Director-Commercial Development at Pfizer Inc. and Daiichi Medical Research, Inc. He also served as Senior VP-Strategic Planning & Business Operations at Nabi Biopharmaceuticals from 2011 to 2012.
Additionally, he worked as Senior Vice President-Business Development at Genaissance Pharmaceuticals, Inc. and as Principal at Pharmacia Corp.
He was EVP & Head-Business Development at VistaGen Therapeutics, Inc. Furthermore, he served as President & Chief Operating Officer at Seneca Biopharma, Inc. from 2020 to 2021.
Dr. Kalnik obtained graduate and doctorate degrees from The Trustees of Columbia University in The City of New York.
He also holds an undergraduate degree from The University of North Carolina at Chapel Hill, which was conferred in 1984.
Aktive Positionen von Matthew Kalnik
Unternehmen | Position | Beginn |
---|---|---|
Hedgerow Consulting LLC | Gründer | 04.11.2011 |
Antidote Therapeutics, Inc.
Antidote Therapeutics, Inc. BiotechnologyHealth Technology Antidote Therapeutics, Inc. engages in the provision of nicotine-blocking drugs to treat diseases caused or worsened by nicotine. Its product pipeline include ATI-1013, ATI 3009, and ATI-2000. The company was founded by Matthew Kalnik and is headquartered in Gaithersburg, MD. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Matthew Kalnik
Unternehmen | Position | Ende |
---|---|---|
PALISADE BIO, INC. | Präsident | 17.03.2021 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Geschäftsführer | 05.08.2012 |
Daiichi Medical Research, Inc. | Corporate Officer/Principal | - |
PFIZER, INC. | Corporate Officer/Principal | - |
VistaGen Therapeutics, Inc. /Old/
VistaGen Therapeutics, Inc. /Old/ BiotechnologyHealth Technology VistaGen Therapeutics, Inc. is a South San Francisco-based biotechnology company that focuses on providing clinically relevant, commercially scalable, human stem cell biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. VistaGen's Clinical Trials in a Test Tube platform is designed to generate predictive information that results in reduced probability of clinical trial drug failures, especially failures associated with heart and liver toxicity. VistaGen expects its new-generation stem cell-based human systems biology platform to enhance dramatically the pharmaceutical industry's ability to deliver innovative drugs for some of the world's most challenging diseases and conditions. | Corporate Officer/Principal | - |
Ausbildung von Matthew Kalnik
The Trustees of Columbia University in The City of New York | Doctorate Degree |
The University of North Carolina at Chapel Hill | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
PFIZER, INC. | Health Technology |
Private Unternehmen | 8 |
---|---|
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Health Technology |
Genaissance Pharmaceuticals, Inc.
Genaissance Pharmaceuticals, Inc. BiotechnologyHealth Technology Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT. | Health Technology |
Pharmacia Corp.
Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
VistaGen Therapeutics, Inc. /Old/
VistaGen Therapeutics, Inc. /Old/ BiotechnologyHealth Technology VistaGen Therapeutics, Inc. is a South San Francisco-based biotechnology company that focuses on providing clinically relevant, commercially scalable, human stem cell biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. VistaGen's Clinical Trials in a Test Tube platform is designed to generate predictive information that results in reduced probability of clinical trial drug failures, especially failures associated with heart and liver toxicity. VistaGen expects its new-generation stem cell-based human systems biology platform to enhance dramatically the pharmaceutical industry's ability to deliver innovative drugs for some of the world's most challenging diseases and conditions. | Health Technology |
Seneca Biopharma, Inc.
Seneca Biopharma, Inc. BiotechnologyHealth Technology Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD. | Health Technology |
Hedgerow Consulting LLC | |
Daiichi Medical Research, Inc. | |
Antidote Therapeutics, Inc.
Antidote Therapeutics, Inc. BiotechnologyHealth Technology Antidote Therapeutics, Inc. engages in the provision of nicotine-blocking drugs to treat diseases caused or worsened by nicotine. Its product pipeline include ATI-1013, ATI 3009, and ATI-2000. The company was founded by Matthew Kalnik and is headquartered in Gaithersburg, MD. | Health Technology |